Berna Biotech, the Swiss vaccine producer, has cheered investors holding out for the long-awaited consolidation on the Neuer Markt with a €279m ($256m) offer for rival Rhein Biotech.

Fund managers have been waiting for companies on Germany's embattled high-growth exchange to become takeover targets, but falling share prices have meant potential bidders have been reluctant to commit.